

J Nathaniel Diehl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5893437/publications.pdf>

Version: 2024-02-01

9
papers

832
citations

1163117

8
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

2123
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. <i>Nature Medicine</i> , 2019, 25, 628-640.	30.7	476
2	Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. <i>Cancer Discovery</i> , 2020, 10, 104-123.	9.4	131
3	Gain-of-Function <i>RHOA</i> Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. <i>Cancer Discovery</i> , 2020, 10, 288-305.	9.4	91
4	Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. <i>Cell Reports</i> , 2020, 31, 107764.	6.4	69
5	Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. <i>Cell Reports</i> , 2021, 35, 109291.	6.4	15
6	The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer. <i>Journal of Biological Chemistry</i> , 2021, 297, 101335.	3.4	14
7	CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. <i>Cell Reports</i> , 2021, 37, 110060.	6.4	14
8	Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 762-774.	4.1	9
9	Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer. <i>Advances in Cancer Research</i> , 2022, 153, 101-130.	5.0	8